Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism

What Was Tested

This randomized controlled trial paper looks at Parathyroid Hormone (PTH 1-84).

Their objective was to compare continuous PTH 1-34 delivery, by insulin pump, with twice-daily delivery.

Why It Was Studied

Vitamin D therapy for hypoparathyroidism does not restore PTH-dependent renal calcium reabsorption, which can lead to renal damage.

Who Took Part

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

STUDY PARTICIPANTS AND SETTING: Eight patients with postsurgical hypoparathyroidism (mean ± sd age 46 ± 5.6 yr) participated at a tertiary care referral center.

How the Study Was Run

In design terms this was a randomized, open-label and crossover study.

Because people in this Parathyroid Hormone (PTH 1-84) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Nothing was hidden in this open-label Parathyroid Hormone (PTH 1-84) study: the participants and staff both knew the treatment.

Each person switched between Parathyroid Hormone (PTH 1-84) and the comparison at some point, usually with a gap in between.

In a 6-month, open-label, randomized, crossover trial, PTH 1-34 was delivered by pump or twice-daily sc injection.

After each 3-month study period, serum and 24-h urine mineral levels and bone turnover markers were measured daily for 3 d, and 24-h biochemical profiles were determined for serum minerals and 1,25-dihydroxyvitamin D(3) and for urine minerals and cAMP.

What Was Measured

Topics PubMed links to this paper include Hormone Replacement Therapy, Hypoparathyroidism, Infusion Pumps, Insulin Infusion Systems, Magnesium, Parathyroid Hormone and Phosphorus.

What This Means in Plain Language

The paper is a randomized, open-label and crossover study of Parathyroid Hormone (PTH 1-84).

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2012 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Parathyroid Hormone (PTH 1-84) compound page.